Wemple writes, “Reuters says it hustled to set the record straight: ‘The original Reuters story misstated that ivermectin was ‘effective’ against Omicron in Phase III clinical trials, which are conducted in humans. We corrected this to clarify it had an ‘antiviral effect’ against Omicron and it was shown in joint nonclinical research. After being made aware of the error, we corrected our story immediately.’
“The Erik Wemple Blog asked Reuters about the newsworthiness of the story in its corrected incarnation. ‘We misinterpreted the Kowa announcement and corrected our story promptly to accurately reflect what the company said with the appropriate context,’ responded a Reuters spokesperson.
“We don’t doubt Reuters’s diligence in correcting itself; we doubt only how effective it’ll be. The mistaken report, after all, landed in a country where poison control centers last year were beset by an increase in ivermectin overdose calls — the byproduct of one strain of covid hype/misinformation.”
Read more here.
The Advocate is looking for a savvy reporter to cover the Baton Rouge business scene…
MLex, a LexisNexis company, is an independent news organization for breaking news and forward-looking analysis…
The Austin Business Journal seeks a staff writer to cover economic development in one of…
A Russian court on Saturday placed Sergei Mingazov, a journalist for the Russian edition of…
Justin Nielsen of Investor's Business Daily writes about the newspaper's 40th anniversary. Nielsen writes, "When the…
Clare Fieseler has been hired by Politico and subsidiary E&E News to cover renewable energy,…